Table 1.
Characteristics of the 183 patients with ALK+ advanced NSCLCs before brigatinib.
| Characteristic | Value |
|---|---|
| Age, median ± IQR years | 60 ± 12.7 |
| Sex | |
| Male | 75 (41) |
| Female | 108 (59) |
| Smoking status | |
| Current smoker | 30 (16.4) |
| Never/former smoker | 153 (83.6) |
| Histology | |
| Adenocarcinoma | 178 (97.3) |
| Others | 5 (2.7) |
| ECOG performance score (n = 147) | |
| 0 | 38 (25.9) |
| 1 | 54 (36.7) |
| ≥2 | 55 (37.4) |
| General symptoms | 114 (62.3) |
| Neurological and meningeal symptoms | 47 (25.7) |
| Weight loss >5% (n = 108) | 44 (40.7) |
| Number of metastatic sites (n = 180) | |
| 1 | 36 (20) |
| 2 | 44 (24.4) |
| >2 | 100 (55.6) |
| Metastatic site locations (n = 180) | |
| Central nervous system | 131 (72.8) |
| Lung | 63 (35) |
| Pleura | 34 (18.9) |
| Liver | 48 (26.7) |
| Bone | 82 (45.6) |
| Leptomeningeal carcinomatosis | 13 (7.2) |
| Adrenals | 22 (12.2) |
| Pericardium | 7 (3.9) |
| Others | 66 (36.7) |
| Brain radiotherapy | |
| 1st line | 92 (50.2) |
| 2nd line | 21 (11.5) |
| 3rd line | 13 (7.1) |
| 4th line | 9 (4.9) |
| Before brigatinib | 13 (7.1) |